Quintiles Information Library Custom Feed

Quintiles Forms New Biomarker Research and Development Company

Wed, 18 Jan 2012 06:00:00 -0400

January 18, 2012 – Quintiles announced that it has invested in a new company formed to provide oncology consulting services and new cancer biomarkers, the key to scientific selection of the right drug for the right patient.

Quintiles Completes Acquisition of Advion BioServices

Mon, 07 Nov 2011 06:00:00 -0400

November 7, 2011 – Quintiles’ ability to provide customers with actionable early-stage data to make better development decisions faster has taken a significant step forward with the closing of the previously announced agreement to acquire Advion BioServices, a premier U.S.-based bioanalytical laboratory.

Podcast: Global Biosimilars Outlook

Tue, 11 Oct 2011 11:50:16 -0400

Dr. Amar Kureishi, Regional Chief Medical Officer, Asia-Pacific, Quintiles, discusses the main drivers behind the growth of biosimilars, and offers suggestions for biopharmaceutical companies looking to enter the space.

Quintiles Addresses Key Considerations for Successful Biosimilar Development

Fri, 30 Sep 2011 14:53:19 -0400

September 29, 2011 – Regulatory and commercial considerations are the primary drivers for successful biosimilar development, according to a new report from Quintiles.

Podcast: Strategic Considerations for Biosimilar Development & Commercialization

Fri, 30 Sep 2011 05:11:50 -0400

Deepa Dahal, Principal Consultant, Consulting at Quintiles, and Dr. Nigel Rulewski, Vice President of Global Strategic Drug Development, emphasize an integrated approach to biosimilar development and commercialization.

An Integrated Approach to Biosimilar Development & Commercialization

Thu, 29 Sep 2011 00:00:00 -0400

As the market for biosimilar products continues to grow, many biopharmaceutical companies trying to enter the space are struggling to overcome the unique challenges that developing such products presents. Download the PDF

Quintiles and Population Genetics Technologies Partner

Mon, 16 May 2011 00:00:00 -0400

May 16, 2011 – Quintiles, and Population Genetics Technologies Ltd. (PGT), announced a commercial collaboration to bring genomic testing into mainstream drug development in order to produce safer, more effective medicines.

Dr. Frank Massam

Fri, 13 May 2011 22:01:05 -0400

Dr. Frank Massam discusses the significance of Quintiles' partnership with Population Genetics Technologies Ltd.

Quintiles Joins the I-SPY 2 Breast Cancer Trial

Thu, 14 Apr 2011 08:00:00 -0400

The I-SPY 2 clinical trial involves 800 patients with advanced breast cancer, and employs innovative adaptive trial design and genetic and biological markers from individual patients’ tumors to screen multiple investigational therapies simultaneously.

The US Approval Pathway for Biosimilar Products

Tue, 22 Feb 2011 13:51:36 -0400

The Public Health Service Act allows biosimilars in the US. The law incorporates a specific subsection dealing with biosimilars entitled the Biologics Price Competition and Innovation Act of 2009 (BPCIA). Download the PDF

CMC, Preclinical and Clinical Considerations for Biosimilars and Follow-on Biologics

Wed, 07 Jul 2010 13:54:28 -0400

This article summarizes some of the issues pertaining to biosimilars in Europe that are also likely to impact eventual FOB approval testing in the US. Download the PDF